Orange Book drug · Generic (ANDA)

Pherazine W/ Codeine

Codeine Phosphate; Promethazine Hydrochloride

DiscontinuedANDA 088739 Halsey

Approved

Dec 23, 1988

Strengths

Listed patents

What does the FDA Orange Book show for Pherazine W/ Codeine?

Pherazine W/ Codeine contains Codeine Phosphate; Promethazine Hydrochloride and is the generic drug FDA Orange Book record for ANDA 088739. The application has 1 presentation with strength, dosage-form, route, status, RLD/RS, TE, patent, and exclusivity context. Current inventory and clinical labeling are not established without an application-matched source.

FDA application: ANDA 088739
Application holder: Halsey Drug Co Inc
Product presentations: 1
Marketing categories: Discontinued
Reference roles: None posted
TE codes: None posted
Listed patents: 0
Exclusivity records: 0

Sourced from the official FDA Orange Book data file · snapshot refreshed Jul 02, 2026, 06:34 PM

FDA product-presentation matrix

Every product number in this exact application

Every FDA product presentation under this application, with strength, dosage form and route, marketing status, therapeutic-equivalence code, and reference role.
Product	Strength	Dosage form / route	Marketing status	TE code	Reference role
001	10MG/5ML;6.25MG/5ML	SYRUPORAL	Discontinued	None posted	None posted

Marketing status, TE code, RLD, and RS are presentation-level fields. Never transfer one product number's designation to another presentation.

Who is responsible for this application?

Application holder is not the same as manufacturer

FDA application holder

Halsey Drug Co Inc

The Orange Book identifies this organization as the applicant responsible for ANDA 088739.

Manufacturer status

Not established by the Orange Book

A product-specific FDA label or NDC source must independently identify a manufacturer, labeler, distributor, packager, repackager, or relabeler. The applicant name is not used as a substitute for that evidence.

Regulatory interpretation

What the record means, and what it does not

FDA marketing status

1 presentation listed as on the Discontinued Drug Product List

A discontinued-list entry does not, by itself, show why marketing stopped or whether FDA determined the product was withdrawn for safety or effectiveness.

Therapeutic equivalence

No TE code is posted for this application

No TE code does not mean FDA found the product ineffective or non-equivalent. FDA generally publishes TE evaluations for multisource prescription products; single-source and some other products may have no code.

Patent & exclusivity record

No listed patents or exclusivity records

This means none appear for this application in the current Orange Book files. It is not a freedom-to-operate opinion and does not rule out unlisted patents, regulatory barriers, or product-specific rights.

Same-ingredient landscape

10 other ANDAs and 1 other NDA found

5 of the related ANDA applications are not marked discontinued. Sharing an ingredient does not establish pharmaceutical or therapeutic equivalence; strength, dosage form, route, and TE group still matter.

Which products are meaningfully comparable?

Exact ingredient + dosage form + route cohorts

ANDA 088739 appears in 1 comparison cohort. These groups narrow the same-ingredient landscape, but strength and TE code must still match before interpreting therapeutic equivalence.

Syrup · Oral

Codeine Phosphate; Promethazine Hydrochloride

12 applications

Product rows: 12
Active applications: 5
Active with AB row: 0

Phenergan W/ Codeine · NDA 008306 Promethazine Hydrochloride And Codeine Phosphate · ANDA 214238 Promethazine Hydrochloride And Codeine Phosphate · ANDA 200894 Promethazine Hydrochloride And Codeine Phosphate · ANDA 200386 Promethazine Hydrochloride And Codeine Phosphate · ANDA 090180 Promethazine With Codeine · ANDA 040650

Why are clinical sections unavailable?

Exact application-label matching status

Exact source match queuedQueue ANDA-088739

No exact application-level FDA or DailyMed label match has been reviewed for this application. Approved uses, dosing, warnings, adverse reactions, and clinical evidence remain unavailable rather than being inherited from a related brand, generic, or ingredient record.

Until an exact application match passes human review, this page intentionally omits approved uses, dosing, warnings, adverse reactions, mechanism, and clinical-study summaries. It never inherits those claims from an RLD, brand, generic, or same-ingredient product.

Product detail

ANDA 088739

Discontinued

Strength: 10MG/5ML;6.25MG/5ML
Dosage form: SYRUP
Route: ORAL
Marketing status: Discontinued

Key dates

Approval, patents, exclusivity

Approval
FDA approval date of this drug product.
Dec 23, 1988
38 yr 2 mo ago
Today

Pharmaceutical detail

FDA product record

Active ingredient

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

Strength

10MG/5ML;6.25MG/5ML

Dosage form

SYRUP

Route

ORAL

TE code

Not listed

Application

ANDA 088739

Product number

001

Marketing status

Discontinued

Reference listed drug (RLD)

Reference standard (RS)

Listed patents

Orange Book patent file

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Active-ingredient family

Brand + generics

Generic (ANDA) of Codeine Phosphate; Promethazine Hydrochloride

View full Codeine Phosphate; Promethazine Hydrochloride family

How to use this record responsibly

Scope, limitations, and primary sources

What to verify before making a decision

The applicant is the holder of legal responsibility for the application; the Orange Book does not establish that the applicant manufactured or currently markets every listed product.
RX, OTC, and discontinued are FDA listing categories, not real-time pharmacy inventory or commercial-availability data.
Therapeutic equivalence applies only within the matching ingredient, dosage form, route, strength, and TE-code group; same ingredient alone is insufficient.
Listed patent and exclusivity dates are regulatory intelligence, not legal advice, a freedom-to-operate analysis, or a reliable generic-launch forecast.
The Orange Book is not prescribing information and does not provide indications, dosing, contraindications, adverse reactions, recalls, or current safety communications.

Official FDA references

Data shown here is normalized for search and comparison. When a regulatory, substitution, launch, or legal decision turns on a field, verify it against the current FDA record and the relevant source document.